Trials / Terminated
TerminatedNCT02246686
Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients
A Randomised, Double-blind, Placebo-controlled Multi-centre Study to Investigate the Effectiveness and Safety of STW5-II as add-on Treatment for Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study will investigate efficacy of STW5-II as add-on therapy on the rate to remission in patients with mild to moderate ulcerative colitis in an acute flare.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STW5-II (Iberogast N, BAY98-7410) | Application over 12 weeks 20 drops three time daily |
| DRUG | Placebo | Application over 12 weeks 20 drops three time daily |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-02-01
- Completion
- 2016-04-01
- First posted
- 2014-09-23
- Last updated
- 2016-10-18
Locations
8 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02246686. Inclusion in this directory is not an endorsement.